Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /NATCOPHARM
chevron_leftBack

NATCO Pharma Ltd.

NATCOPHARM
NSE: NATCOPHARM Delayed
844.50INR 0.6%
9.88 USD
As of 24 April 2025, NATCO Pharma Ltd. has a market cap of $1.76B USD, ranking #5825 globally and #398 in India. It ranks #530 in the Healthcare sector, and #110 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
5825
Country Rank
398
Sector Rank
530
Industry Rank
110
Key Stats
Market Cap
$1.76BUSD
150.33B INR
Enterprise Value
$1.5BUSD
127.85B INR
Revenue (TTM)
$501.58MUSD
42.8B INR
EBITDA (TTM)
$252.16MUSD
21.56B INR
Net Income (TTM)
$218.57MUSD
18.65B INR
EBITDA Margin
50%
Profit Margin
44%
PE Ratio
8.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Rajeev Nannapaneni open_in_new
Employees
4,016
Founded
1981
Website
natcopharma.co.in open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.6% 4.4% 1.2% -32% -39% -16%
Upcoming Earnings
Earnings Date
Tue, May 27

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
NATCOPHARM
Natco Pharma Ltd
ISIN: INE987B01026
Shares Out.:
179.11M1 Shares Float: 86.731M2
TV:
SA:
YF:
GF:
BA:
MS:
844.50 INR
Bombay Stock Exchange
MIC: XBOM
524816 (NATCOPHARM)
Natco Pharma Ltd
ISIN: INE987B01026
TV:
SA:
YF:
GF:
BA:
MS:
839.40 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About NATCO Pharma Ltd.

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
3K%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
944%
Cipla Ltd.
CIPLA
$14.46B
1.23T INR
721%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
651%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
608%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
4K%
Merck KGaA
MRK
$59.42B
52.43B EUR
3K%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
3K%
Haleon plc
HLN
$45.57B
34.34B GBP
2K%
Galderma Group AG
GALD
$23.06B
19.13B CHF
1K%